ATE416764T1 - Behandlungsmethoden während eingriffen in das gefässsystem - Google Patents

Behandlungsmethoden während eingriffen in das gefässsystem

Info

Publication number
ATE416764T1
ATE416764T1 AT03809618T AT03809618T ATE416764T1 AT E416764 T1 ATE416764 T1 AT E416764T1 AT 03809618 T AT03809618 T AT 03809618T AT 03809618 T AT03809618 T AT 03809618T AT E416764 T1 ATE416764 T1 AT E416764T1
Authority
AT
Austria
Prior art keywords
treatment methods
vascular system
vascular
methods during
during interventions
Prior art date
Application number
AT03809618T
Other languages
English (en)
Inventor
Roshantha Chandraratna
Yang-Dar Yuan
Tuong Dang
Sheng Loh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE416764T1 publication Critical patent/ATE416764T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03809618T 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem ATE416764T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/278,770 US7105566B2 (en) 2002-10-22 2002-10-22 Methods of treatment during vascular procedures

Publications (1)

Publication Number Publication Date
ATE416764T1 true ATE416764T1 (de) 2008-12-15

Family

ID=32093435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03809618T ATE416764T1 (de) 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem

Country Status (6)

Country Link
US (1) US7105566B2 (de)
EP (1) EP1558235B1 (de)
AT (1) ATE416764T1 (de)
AU (1) AU2003301673A1 (de)
DE (1) DE60325261D1 (de)
WO (1) WO2004037243A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054468A1 (ja) * 2003-12-01 2005-06-16 Reverse Proteomics Research Institute Co., Ltd. 抗糖尿病剤の標的タンパク質及び対応する新規抗糖尿病剤「インスフル」
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
JP2009537540A (ja) * 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
GB0915196D0 (en) * 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
CN104114171A (zh) 2011-12-13 2014-10-22 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
CN115252789A (zh) 2016-03-10 2022-11-01 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CN115335367A (zh) * 2019-12-19 2022-11-11 奥弗恩制药公司 用于炎性疾病和雄性避孕的RAR-α化合物
US11998521B2 (en) 2021-12-07 2024-06-04 Io Therapeutics, Inc. Use of an RXR agonist in treating drug resistant HER2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2129846A1 (en) 1992-12-28 1994-07-07 Norimasa Miyamoto Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US6008204A (en) * 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
EP0873295B1 (de) * 1995-10-06 2003-04-02 Ligand Pharmaceuticals, Inc. Dimer-selektive rxr modulatoren und verfahren zu ihrer verwendung
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US6037488A (en) * 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
BR9814957A (pt) * 1997-11-12 2000-10-03 Hoffmann La Roche Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
US6521641B1 (en) * 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
US20050009868A1 (en) * 2001-09-17 2005-01-13 Underhill Michael Tully Retinoid receptor pan-antagonists for stimulating chondrogenesis

Also Published As

Publication number Publication date
AU2003301673A1 (en) 2004-05-13
WO2004037243A2 (en) 2004-05-06
US7105566B2 (en) 2006-09-12
EP1558235B1 (de) 2008-12-10
EP1558235A2 (de) 2005-08-03
DE60325261D1 (de) 2009-01-22
WO2004037243A3 (en) 2004-09-30
US20040077710A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
Schaden et al. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study
Hirokawa et al. Comparison of 1470 nm laser and radial 2ring fiber with 980 nm laser and bare-tip fiber in endovenous laser ablation of saphenous varicose veins: a multicenter, prospective, randomized, non-blind study
ATE416764T1 (de) Behandlungsmethoden während eingriffen in das gefässsystem
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE506019T1 (de) Kontrollierbare vorrichtung und kit zur behandlung von störungen des herzrhythmus- reguliersystems
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
NO20060498L (no) Metode for a promotere benvekst
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
ATE424824T1 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
NO20021410L (no) Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
WO2003082263A8 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
Sabry et al. Cross-leg flaps: Case series, review, and proposed classification
Chidiac et al. Outpatient continuous peripheral nerve catheters
RU2284155C1 (ru) Способ субфасциальной диссекции перфорантных вен голени при хронической венозной недостаточности
RU2532302C1 (ru) Способ лечения больных с эпикондилитом
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
UA78009U (uk) Спосіб хірургічного лікування варикозних вен нижніх кінцівок

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties